Infraestructura de Medicina de Precisión asociada a la Ciencia y la Tecnología
IMPaCT MEETING
18 Nov 2024 – form 09:30 to 18:00

Longitudinal integration of patient-generated data and multi-omics determinations for comprehensive precision oncology in women’s cancer.

PMP22/00032
Year: 2022
Autonomous Communities: MADRID

Axes of Affiliation

Line of research

Project Video

Summary

Cancer treatment has advanced a lot thanks to the implementation of targeted therapies that implement specific treatments according to the genetic profile of the tumors. However, even in the best cases, 20 to 30% of patients do not respond to these treatments. The HDO project aims to improve cancer treatments by looking beyond genetics and considering other factors that influence disease development and response to treatment. These factors include things like DNA methylation, gut microbiota, or the patient’s physiology. By combining these factors with genetic information, we move from precision oncology to high-definition oncology. With this approach we can obtain a much more detailed view of the disease and identify the key factors that affect its evolution.

HDO plans to monitor 300 patients with metastatic cancer, collecting clinical, molecular, and physiological data, as well as patient-generated data through quality of life and nutrition questionnaires.

Through this information, the project seeks to trace the different trajectories that the disease can follow and discover what are the factors that determine the evolution towards different outcomes and towards different levels of quality of life.

The project integrates clinical oncology, engineering and data science, and represents the most comprehensive high-definition oncology study to date in metastatic cancers.

XYZ’s ultimate goal is to bring benefits to cancer patients and advance the field of oncology by overcoming the current barriers of precision medicine.

Coordinator and Institution

Principal Investigator
Miguel Ángel Quintela Fandiño
Institution
Objectives
  • To improve the predictive capacity and efficacy of the treatment of metastatic breast, lung, and colorectal cancers by using a high-definition medical approach.
  • To analyze longitudinal and multimodal data from 300 patients with metastatic cancer to create disease models that identify the determining causes of the clinical course of the disease.
Impact
  • The study will reveal the links between molecular profiles, physiological data and clinical events, leading to the identification of new candidates for markers and therapeutic targets that improve patient care and increase their benefit.
  • HDO will provide a study of metastatic breast, lung and colorectal cancer with an unprecedented level of detail that will allow for a better understanding of the disease.
  • The project will demonstrate the feasibility and effectiveness of the high-definition medicine approach, which will help drive the use of a more holistic view of patients in both oncology and other clinical settings.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.